Literature DB >> 17934521

1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas.

K Ichimura1, A P Vogazianou, L Liu, D M Pearson, L M Bäcklund, K Plant, K Baird, C F Langford, S G Gregory, V P Collins.   

Abstract

Astrocytic, oligodendroglial and mixed gliomas are the commonest gliomas in adults. They have distinct phenotypes and clinical courses, but as they exist as a continuous histological spectrum, differentiating them can be difficult. Co-deletions of total 1p and 19q are found in the majority of oligodendrogliomas and considered as a diagnostic marker and a prognostic indicator. The 1p status of astrocytomas has not yet been thoroughly examined. Using a chromosome 1 tile path array, we investigated 108 adult astrocytic tumours for copy number alterations. Total 1p deletions were rare (2%), however partial deletions involving 1p36 were frequently identified in anaplastic astrocytomas (22%) and glioblastomas (34%). Multivariate analysis showed that patients with total 1p deletions had significantly longer survival (P=0.005). In nine glioblastomas homozygous deletions at 1p36 were identified. No somatic mutations were found among the five genes located in the homozygously deleted region. However, the CpG island of TNFRSF9 was hypermethylated in 19% of astrocytic tumours and 87% of glioma cell lines. TNFRSF9 expression was upregulated after demethylation of glioma cell lines. Akt3 amplifications were found in four glioblastomas. Our results indicate that 1p deletions are common anaplastic astrocytomas and glioblastomas but are distinct from the 1p abnormalities in oligodendrogliomas.

Entities:  

Mesh:

Year:  2007        PMID: 17934521      PMCID: PMC2650419          DOI: 10.1038/sj.onc.1210848

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.

Authors:  Y Ino; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; S Jhung; D A Ramsay; A von Deimling; D N Louis; J G Cairncross
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

2.  Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors.

Authors:  A von Deimling; R Fimmers; M C Schmidt; B Bender; F Fassbender; J Nagel; R Jahnke; P Kaskel; E M Duerr; J Koopmann; D Maintz; S Steinbeck; W Wick; M Platten; D J Müller; R Przkora; A Waha; B Blümcke; R Wellenreuther; B Meyer-Puttlitz; O Schmidt; J Mollenhauer; A Poustka; A P Stangl; D Lenartz; K von Ammon
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

3.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay.

Authors:  J M Nigro; M A Takahashi; D G Ginzinger; M Law; S Passe; R B Jenkins; K Aldape
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  Absence of mutation of the p73 gene in astrocytic neoplasms.

Authors:  M E Alonso; M J Bello; J Lomas; P Gonzalez-Gomez; D Arjona; J M De Campos; M Gutierrez; A Isla; J Vaquero; J A Rey
Journal:  Int J Oncol       Date:  2001-09       Impact factor: 5.650

6.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.

Authors:  K Ichimura; M B Bolin; H M Goike; E E Schmidt; A Moshref; V P Collins
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

7.  Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.

Authors:  E E Schmidt; K Ichimura; H M Goike; A Moshref; L Liu; V P Collins
Journal:  J Neuropathol Exp Neurol       Date:  1999-11       Impact factor: 3.685

8.  Protein binding of a DRPLA family through arginine-glutamic acid dipeptide repeats is enhanced by extended polyglutamine.

Authors:  H Yanagisawa; M Bundo; T Miyashita; Y Okamura-Oho; K Tadokoro; K Tokunaga; M Yamada
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

9.  Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis.

Authors:  T Waerner; P Gardellin; K Pfizenmaier; A Weith; N Kraut
Journal:  Cell Growth Differ       Date:  2001-04

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  32 in total

Review 1.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

Review 3.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

4.  MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer.

Authors:  Yan Sun; Ping Ji; Tao Chen; Xinhui Zhou; Da Yang; Yuhong Guo; Yuexin Liu; Limei Hu; Dianren Xia; Yanxue Liu; Asha S Multani; Ilya Shmulevich; Raju Kucherlapati; Scott Kopetz; Anil K Sood; Stanley R Hamilton; Baocun Sun; Wei Zhang
Journal:  J Pathol       Date:  2016-11-24       Impact factor: 7.996

5.  RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration.

Authors:  Peng-Jin Mei; Jin Bai; Hui Liu; Chen Li; Yong-Ping Wu; Zheng-Quan Yu; Jun-Nian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-16       Impact factor: 4.553

Review 6.  Diverse mechanisms of AKT pathway activation in human malignancy.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Curr Cancer Drug Targets       Date:  2013-03       Impact factor: 3.428

7.  Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).

Authors:  Oliver Grauer; Christina Pascher; Christian Hartmann; Florian Zeman; Michael Weller; Martin Proescholdt; Alexander Brawanski; Thorsten Pietsch; Wolfgang Wick; Ulrich Bogdahn; Peter Hau
Journal:  J Neurooncol       Date:  2011-03-04       Impact factor: 4.130

8.  Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

Authors:  Ross C Laxton; Sergey Popov; Lawrence Doey; Alexa Jury; Ranj Bhangoo; Richard Gullan; Chris Chandler; Lucy Brazil; Gill Sadler; Ron Beaney; Naomi Sibtain; Andrew King; Istvan Bodi; Chris Jones; Keyoumars Ashkan; Safa Al-Sarraj
Journal:  Neuro Oncol       Date:  2013-10-24       Impact factor: 12.300

9.  Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.

Authors:  Christopher G Duncan; Patrick J Killela; Cathy A Payne; Benjamin Lampson; William C Chen; Jeff Liu; David Solomon; Todd Waldman; Aaron J Towers; Simon G Gregory; Kerrie L McDonald; Roger E McLendon; Darell D Bigner; Hai Yan
Journal:  Oncotarget       Date:  2010-08

10.  Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.

Authors:  Mathilde C M Kouwenhoven; Thierry Gorlia; Johan M Kros; Ahmed Ibdaih; Alba A Brandes; Jacolien E C Bromberg; Karima Mokhtari; Sjoerd G van Duinen; Johannes L Teepen; Pieter Wesseling; Fanny Vandenbos; Wolfgang Grisold; László Sipos; Rene Mirimanoff; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.